Natco and Lupin receive USFDA approval for Eribulin Mesylate Injection, a treatment for metastatic breast cancer.

Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for ...

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance ...

NATCO Pharma Limited and its alliance partner Lupin Limited has announced the approval from the United States Food and Drug ...

Lupin and Hyderabad-based Natco Pharma have received USFDA approval for Eribulin Mesylate Injection, a generic version of Halaven used to treat metastatic breast cancer and advanced liposarcoma. The ...

NATCO Pharma announced that its alliance partner, Lupin, has received approval from the United States Food and Drug Administration (USFDA) for NATCO's abbreviated new drug application (ANDA) for ...

Pharma major Lupin Limited and its alliance partner Natco Pharma Limited announced the approval from the United States Food and Drug Administration (FDA) for the latter's Abbreviated New Drug ...

Natco Pharma and Lupin receive U.S. FDA approval for generic Eribulin Mesylate, a treatment for metastatic breast cancer.

On Wednesday, 1,812 stocks advanced, 2,400 declined and 183 remained unchanged on Bombay Stock Exchange with advance decline ...

Rodrigo Munhoz, MD, of the Oncology Center-Hospital Sírio-Libanês of São Paulo, Brazil, commented that by "meeting its ...